OncoDaily

ROSELLA Trial at ASCO 2026: Relacorilant Improves OS in Ovarian Cancer

The ROSELLA trial brought a new mechanism to the ASCO 2026 stage in one of oncology’s most stubborn settings: platinum-resistant ovarian cancer, where chemotherapy options are limited and survival has changed little in years. Presented by Lucy Gilbert, MD, MSc from McGill University Health Centre, Montreal, the analysis reported final overall survival (OS) results — and asked a question that matters to every patient facing this diagnosis: can adding a glucocorticoid receptor antagonist to chemotherapy help them live longer?

Relacorilant is a first-in-class, selective glucocorticoid receptor antagonist designed to restore tumor sensitivity to chemotherapy-induced cell death. ROSELLA tested whether combining it with weekly nab-paclitaxel could outperform nab-paclitaxel alone — the most active single-agent chemotherapy in this disease — and the trial was designed around the two endpoints that define a meaningful advance: progression-free survival and overall survival.

Read more:
https://oncodaily.com/trial-updates/rosella-trial-asco-2026

The Yvonne Awards Ceremony by OncoDaily Was Truly Oscar-Worthy - Amalya Sargsyan

Red carpet, beautiful dresses, oncologists, researchers, leaders, and of course, the greatest reception.

It was such an honor to co-present the Breakthrough Research Award with a very special person, Dr. Garo Armen, scientist, entrepreneur, philanthropist, global leader, and co-founder and CEO of Agenus.

Read more:
https://oncodaily.com/voices/amalya-sargsyan-513777